Advancements in nanotechnology for drug delivery
A review of recent innovations in Pharmacy-GIT as a model
Keywords:
nanoparticles, drug delivery, gastrointestinal tract, inflammatory bowel disease, colorectal cancer, lipid nanoparticlesAbstract
Background: Nanoparticles (NPs) have emerged as a transformative technology in drug delivery, offering advancements in precision medicine, especially in managing chronic diseases and gastrointestinal (GIT) disorders. Due to their unique properties and the ability to be engineered at the nanoscale, NPs provide enhanced targeting, controlled release, and reduced side effects compared to traditional drug delivery systems. Aim: This review aims to summarize recent innovations in nanoparticle technology and their applications in drug delivery systems, with a focus on gastrointestinal diseases. Methods: The review synthesizes current literature on NP technologies and their applications in treating GIT disorders. It covers a range of nanocarriers, including metal and polymeric NPs, liposomes, hydrogels, and lipid nanoparticles. The review evaluates their effectiveness, challenges, and advancements in GIT drug delivery. Results: Recent advancements in NP technology have demonstrated significant potential in improving drug delivery to the GIT. Innovations include pH-sensitive NPs, enzyme-responsive NPs, and targeted formulations for diseases such as inflammatory bowel disease (IBD) and colorectal cancer. Lipid nanoparticles, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), have shown promise in enhancing stability, targeting, and drug release profiles.
Downloads
References
Jayant R, Nair M. Nanotechnology for the Treatment of NeuroAIDS. J Nanomedicine Res. 2016;3(1):00047.
Kaushik A, Jayant RD, Nair M. Advancements in nano-enabled therapeutics for neuroHIv management. Int J Nanomedicine. 2016;11:4317.
Tomitaka A, Arami H, Raymond A, et al. Development of magneto-plasmonic nanoparticles for multimodal image-guided therapy to the brain. Nanoscale. 2017;9(2):764-773.
Vashist A, Kaushik A, Vashist A, et al. Recent trends on hydrogel based drug delivery systems for infectious diseases. Biomater Sci. 2016;4(11):1535-1553.
De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133
Gulbake A, Jain A, Jain A, et al. Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol. 2016;22(2):582.
Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971-3010.
Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58(3):673-80.
Yassin AM, El-Deeb NM, Metwaly AM, et al. Induction of apoptosis in human cancer cells through extrinsic and intrinsic pathways by Balanites aegyptiaca Furostanol Saponins and saponin-coated silver nanoparticles. Appl Biochem Biotechnol. 2017; 182:1675-1693.
Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-232.
Higa LH, Jerez HE, de Farias MA, et al. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine (Lond). 2017;12(10):1165-1175.
Jiang H, Geng D, Liu H, et al. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv. 2016;23(9):3665-3673
Pertuit D, Moulari B, Betz T, et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 2007;123(3):211-218.
Naeem M, Cao J, Choi M, et al. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. Int J Nanomedicine. 2015;10:4565-4580.
Naeem M, Choi M, Cao J, et al. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther. 2015;9:3789-3799.
Chellat F, Merhi Y, Moreau A, et al. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials. 2005;26:7260-7275. (*This manucsript discusses the potential thereputic role of nanoparticles for macrophage-mediated therapies.)
Wachsmann P, Lamprecht A. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. Methods Enzymol. 2012;508:377-397.
Rejman J, Oberle V, Zuhorn IS, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1):159- 169.
Si X-Y, Merlin D, Xiao B. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J Gastroenterol. 2016;22(34):7718.
Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017; 25:1628-1640.
Feng M, Zhong L, Zhan Z, et al. Enhanced antitumor efficacy of resveratrol-loaded nanocapsules in colon cancer cells: physicochemical and biological characterization. Eur Rev Med Pharmacol Sci. 2017;21:375-382.
Xie Y, Murray-Stewart T, Wang Y, et al. Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy. J Controlled Release. 2017;246:110-119.
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivery Rev. 2003 55:329-347.
Salatin S, Maleki Dizaj S, Yari Khosroushahi A. Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int. 2015;39(8):881-890.
Riasat R, Guangjun N, Riasat Z, et al. Effects of Nanoparticles on Gastrointestinal Disorders and Therapy. J Clin Toxicol. 2016;6(4
Crucho CIC, Barros MT. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Mater Sci Eng C Mater Biol Appl. 2017; 80:771-784.
Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol. 2014; 12(10):1605-1610.
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70(1-2):1-20.
Kolawole OM, Lau WM, Mostafid H, Khutoryanskiy VV. Advances in intravesical drug delivery systems to treat bladder cancer. Int J Pharm. 2017; 532(1):105-117.
Lee SM, Chen H, Dettmer CM, O'Halloran TV, Nguyen ST. Polymer-caged lipsomes: a pHresponsive delivery system with high stability. J Am Chem Soc. 2007; 129(49):15096-15097.
Sihorkar V, Vyas SP. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J Pharm Pharm Sci. 2001;4(2):138-158.
Sharpe LA, Daily AM, Horava SD, Peppas NA. Therapeutic applications of hydrogels in oral drug delivery. Expert Opin Drug Deliv. 2014; 11(6):901-915.
Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev. 2008; 60(15):1638-1649.
Capek I. Polymer decorated gold nanoparticles in nanomedicine conjugates. Adv Colloid Interface Sci. 2017 (in press).
Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine. 2012; 7:3445-3471. (*This review aims to understand the superparamagnetic iron oxide nanoparticles as a magnetic nanoplatforms as drug carries.)
Cheng Y, A CS, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc. 2008; 130(32):10643-7.
Polizzi MA, Stasko NA, Schoenfisch MH. Water-soluble nitric oxide-releasing gold nanoparticles. Langmuir. 2007; 23(9):4938-4943.
Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2001;299(2):775-781. Downloaded by [University of New England] at 17:25 24 December 2017 Accepted Manuscript 34
Lamprecht A, Ubrich N, Yamamoto H, et al. Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J Control Release. 2001;71(3):297-306.
Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm. 2006;316(1-2):138-43
Laroui H, Geem D, Xiao B, et al. Targeting intestinal inflammation with CD98 siRNA/PEIloaded nanoparticles. Mol Ther. 2014;22(1):69-80.
Roy U, Ding H, Pilakka-Kanthikeel S, et al. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue. Int J Nanomedicine. 2015;10:5819-35.
Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454(2):775-83.
Badamaranahalli SS, Kopparam M, Bhagawati ST, et al. Embelin lipid nanospheres for enhanced treatment of ulcerative colitis - Preparation, characterization and in vivo evaluation. Eur J Pharm Sci. 2015;76:73-82.
Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut. 2007;56(3):343-350.
Kotelevets L, Chastre E, Desmaële D, et al. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. Int J Pharmaceutics. 2016;514(1):24-40.
Rodriguez-Nogales A, Algieri F, Laura De Matteis A, et al. Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acidinduced experimental colitis in rats. Int J Nanomedicine. 2016;11:5945.
Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321-340.
Siczek K, Zatorski H, Chmielowiec-Korzeniowska A, et al. Synthesis and evaluation of antiinflammatory properties of silver nanoparticle suspensions in experimental colitis in mice. Chem Biol Drug Des. 2017; 89:538-547.
Lee Y, Kim H, Kang S, et al. Bilirubin Nanoparticles as a Nanomedicine for Antiinflammation Therapy. Angew Chem Int Ed Engl. 2016;55(26):7460-7463.
Guo J, Jiang X, Gui S. RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine. 2016;11:5287-5310.
Zhang Q, Tao H, Lin Y, et al. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials. 2016;105:206-221.
Karban A, Nakhleh MK, Cancilla JC, et al. Programmed nanoparticles for tailoring the detection of inflammatory bowel diseases and irritable bowel syndrome disease via breathprint. Adv Healthcare Materials. 2016;5(18):2339-2344.
Kotelevets L, Chastre E, Desmaële D, et al. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. Int J Pharmaceutics. 2016;514(1):24-40.
González-Ballesteros N, Prado-López S, Rodríguez-González JB, et al. Green synthesis of gold nanoparticles using brown algae Cystoseira baccata: Its activity in colon cancer cells. Colloids and Surfaces B: Biointerfaces. 2017;153:190-198. Downloaded by [University of New England] at 17:25 24 December 2017 Accepted Manuscript 36
Hou X, Yang C, Zhang L, et al. Killing colon cancer cells through PCD pathways by a novel hyaluronic acid-modified shell-core nanoparticle loaded with RIP3 in combination with chloroquine. Biomaterials. 2017;124:195-210.
Vassie JA, Whitelock JM, Lord MS. Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells. Acta Biomaterialia. 2017;50:127-141.
Edelman R, Assaraf YG, Levitzky I, et al. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy. Oncotarget. 2017; 8:24337-24353.
Sheen MR, Fiering S. Exploiting uptake of nanoparticles by phagocytes for cancer treatment. Methods Mol Biol. 2017; 1530:355-367
Lin T, Yuan A, Zhao X, et al. Self-assembled tumor-targeting hyaluronic acid nanoparticles for photothermal ablation in orthotopic bladder cancer. Acta Biomaterialia. 2017;53:427-438.
Wei F, Wang Y, Luo Z, et al. New findings of silica nanoparticles induced ER autophagy in human colon cancer cell. Sci Reports. 2017;7:42591.
Beik J, Abed Z, Ghadimi-Daresajini A, et al. Measurements of nanoparticle-enhanced heating from 1MHz ultrasound in solution and in mice bearing CT26 colon tumors. J Ther Biol. 2016;62:84-89.
Dianzani C, Foglietta F, Ferrara B, et al. Solid lipid nanoparticles delivering antiinflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model. World J Gastroenterol. 2017;23(23):4200-10
Guada M, Beloqui A, Alhouayek M, et al. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease. Int J Pharmaceutics. 2016;503(1):196-8.
Yassin AE, Anwer MK, Mowafy HA, et al. Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer.Int J Med Sci. 2010;7(6):398-408.
Naseri N, Valizadeh H, Zakeri-Milani P. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull. 2015;5(3):305-313
Asghar LF, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci. 2006;9(3):327-338.
Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161(2):235-246.
Lamprecht A. IBD: selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol Hepatol. 2010;7(6):311-312.
Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788-793.
Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 1996;14(17-18):1677-1685.
Serra L, Domenech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm. 2009;71(3):519-528. Downloaded by [University of New England] at 17:25 24 December 2017 Accepted Manuscript 38
Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315(1):196-202.
Yoshitomi T, Sha S, Vong LB, et al. Indomethacin-loaded redox nanoparticles improve oral bioavailability of indomethacin and suppress its small intestinal inflammation. Ther Deliv. 2014;5(1):29-38.
Karavolos M, Holban A. Nanosized drug delivery systems in gastrointestinal targeting: interactions with microbiota. Pharmaceuticals (Basel). 2016;9(4).
Antoni L, Nuding S, Wehkamp J, et al. Intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2014;20(5):1165-1179. 77. Hua S, Marks E, Schneider JJ, et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11(5):1117-1132.
Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001(234):29-40.
Rana SV, Sharma S, Malik A, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58(9):2594-2598.
Kashyap PC, Marcobal A, Ursell LK, et al. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterol. 2013;144(5):967-977. Downloaded by [University of New England] at 17:25 24 December 2017 Accepted Manuscript 39
Keely S, Kelly CJ, Weissmueller T, et al. Activated fluid transport regulates bacterialepithelial interactions and significantly shifts the murine colonic microbiome. Gut Microbes. 2012;3(3):250-260.
Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int J Pharmaceutics. 2006
Mittal, R., Patel, A. P., Jhaveri, V. M., Kay, S. I. S., Debs, L. H., Parrish, J. M., ... & Jayant, R. D. (2018). Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders. Expert opinion on drug delivery, 15(3), 301-318.
Published
How to Cite
Issue
Section
Copyright (c) 2018 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
